MSLN and neoplasm: Several clinical trials have tested human primary NK cells modified with CARs targeting specific tumor antigens, including ROBO1 for solid tumors (NCT03940820), PSMA for prostate cancer (NCT03692663), MSLN for epithelial ovarian cancer (NCT03692637), and Claudin6 for ovarian, testicular, and refractory endometrial cancers (NCT05410717).